pirprofen has been researched along with etodolac in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beroza, P; Cai, D; Damodaran, K; Gomez, RF; Hsu, N; Keck, JG; Laborde, E; Lum, RT; Macke, TJ; Martin, G; Schow, SR; Simon, RJ; Villar, HO; Wick, MM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for pirprofen and etodolac
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for pirprofen and etodolac
| Article | Year |
|---|---|
Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Combinatorial Chemistry Techniques; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Ibuprofen; Inhibitory Concentration 50; Isoenzymes; Models, Molecular; Models, Theoretical; Molecular Structure; Prospective Studies; Prostaglandin-Endoperoxide Synthases; Quantitative Structure-Activity Relationship | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |